Skip to content

Inspection Record

Shimoga Chemicals — FDA 483 Findings

US FDAInspected 2026-01-23Published 2026-10-23 10 findingsProcess validationDeviation, CAPA, and investigationStability and storageDocumentation and recordsLaboratory and QC controlsValidation and qualificationQuality unit oversightEquipment and facility

Inspectors Rachael A Moss · Arsen KarapetyanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

2Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

3Stability and storage

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

4Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

5Laboratory and QC controls

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.

6Validation and qualification

Failure to ensure training is regularly conducted by qualified individuals and covers, at a minimum, the particular operations that each employee performs and CGMP as they relate to the employee’s functions.

7Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

8Equipment and facility

Procedures for the cleaning and maintenance of equipment and its release for use in the manufacture of intermediates and API are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembly of equipment as necessary to assure proper cleaning and maintenance.

9Equipment and facility

Buildings used in the holding of active pharmaceutical ingredient do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

10Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and raw materials conform to appropriate standards of identity.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Shimoga Chemicals findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.